SRR8518454
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.700
- INTERFERON_GAMMA_RESPONSE+0.670
- ALLOGRAFT_REJECTION+0.600
- IL6_JAK_STAT3_SIGNALING+0.560
- INFLAMMATORY_RESPONSE+0.530
- COMPLEMENT+0.450
- TNFA_SIGNALING_VIA_NFKB+0.440
- IL2_STAT5_SIGNALING+0.420
- UV_RESPONSE_DN+0.400
- KRAS_SIGNALING_UP+0.370
Top 10 suppressed
- CHOLESTEROL_HOMEOSTASIS-0.380
- OXIDATIVE_PHOSPHORYLATION-0.380
- MYC_TARGETS_V2-0.350
- DNA_REPAIR-0.310
- MYC_TARGETS_V1-0.310
- ADIPOGENESIS-0.300
- BILE_ACID_METABOLISM-0.290
- ESTROGEN_RESPONSE_LATE-0.250
- MTORC1_SIGNALING-0.250
- FATTY_ACID_METABOLISM-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8613789 | — | A | 0.890 |
| 2 | SRR8613773 | — | A | 0.886 |
| 3 | TCGA-69-7978-01A-11R-2187-07 | — | cohortA1 | 0.884 |
| 4 | TCGA-55-6971-01A-11R-1949-07 | — | cohortMD2 | 0.878 |
| 5 | DRR168577 | — | — | 0.878 |
| 6 | SRR8518406 | — | D | 0.873 |
| 7 | TCGA-E2-A1B1-01A-21R-A12P-07 | — | A | 0.870 |
| 8 | SRR8613774 | — | D | 0.866 |
| 9 | SRR8518387 | — | D | 0.866 |
| 10 | TCGA-BH-A0BF-01A-21R-A12P-07 | — | D | 0.863 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.700 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.670 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.600 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.560 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.530 | Idelalisib | — uncovered |
| COMPLEMENT | 0.450 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.440 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.420 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.400 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.370 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.300 | Inavolisib | — uncovered |
| APOPTOSIS | 0.270 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.260 | Inavolisib | — uncovered |
| COAGULATION | 0.230 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.230 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.120 | Temsirolimus | — uncovered |
| TGF_BETA_SIGNALING | 0.110 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.100 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.090 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.080 | Remibrutinib | — uncovered |